Lyme Disease Testing Explained

Lyme Testing Explained — scientific infographic poster

Table of Contents

  1. Why Lyme Testing Is Confusing
  2. Standard Two-Tier Testing (STTT)
  3. Modified Two-Tier Testing (MTTT)
  4. The Early-Window Problem
  5. Western Blot Band Interpretation
  6. False Positives — Other Causes
  7. When Testing Helps — And When It Does Not
  8. Polymerase Chain Reaction Testing
  9. Culture
  10. Cerebrospinal Fluid Testing for Neuroborreliosis
  11. C6 Peptide ELISA
  12. "Chronic Lyme" Tests Outside the CDC Criteria
  13. Seronegative Lyme
  14. Post-Treatment Serology
  15. Special Populations
  16. Key Research Papers
  17. Connections
  18. Featured Videos

Why Lyme Testing Is Confusing

If you have spent any time trying to figure out whether you have Lyme disease, you have already collided with the central frustration of this illness: there is no simple blood test that directly looks for the bacterium. Standard Lyme testing does not detect Borrelia burgdorferi itself. It detects the antibodies your immune system makes against Borrelia, which is a very different thing.

This matters for three reasons. First, antibodies take weeks to appear, so a test run during the first infection window is often negative even when you clearly have Lyme. Second, antibodies persist for years after successful treatment, so you cannot retest later to prove the bacteria are gone. And third, other infections and autoimmune conditions can generate antibodies that cross-react with the Lyme assay, producing false positives.

Most of the confusion, controversy, and despair that surrounds Lyme diagnosis traces back to this single fact. The test is indirect. The clinical picture — the rash, the tick exposure, the pattern of symptoms, the season — carries more weight than the lab result, especially early on. A good Lyme workup is a physician reading the story and using serology as one piece of evidence, not as a yes/no verdict.

Standard Two-Tier Testing (STTT)

The U.S. Centers for Disease Control and Prevention (CDC) has recommended a two-step strategy since 1995. It is the protocol most hospital and commercial labs still run when your clinician orders a "Lyme panel."

Step 1 — ELISA or indirect fluorescent antibody (IFA) screen. An enzyme-linked immunosorbent assay (ELISA) looks for antibodies against a mixture of Borrelia antigens. It is designed to be sensitive, meaning it casts a wide net and catches most true positives, accepting that it will also flag some people who do not actually have Lyme.

Step 2 — Western blot confirmation. If the ELISA is positive or equivocal, the same blood sample is run on a Western blot, which separates Borrelia proteins by size on a gel and checks which specific bands your antibodies are attacking. Two blots are run: an immunoglobulin M (IgM) blot (early-phase antibodies) and an immunoglobulin G (IgG) blot (mature antibodies that appear weeks later).

A negative ELISA ends the workup — no blot is run, and the result is reported simply as negative. This is the design that misses early Lyme: if you test in the first two weeks of infection before antibodies have developed, the ELISA is negative and no further testing happens, even though you may be acutely infected.

Modified Two-Tier Testing (MTTT)

On July 29, 2019, the U.S. Food and Drug Administration (FDA) cleared several Lyme assays for this use, and on August 16, 2019, the U.S. Centers for Disease Control and Prevention published its acceptance of an alternative: modified two-tier testing, which replaces the Western blot with a second ELISA that targets different antigens than the first. Both steps are now enzyme immunoassays; the second confirms the first by looking at a distinct set of Borrelia surface proteins (commonly VlsE and C6).

The MTTT offers real advantages. Sensitivity in early disease is higher than STTT in the published comparisons, because the newer assays pick up antibodies against antigens that appear earlier in infection. In a 2017 study of 55 patients with acute EM rash, the modified protocols detected 36% to 54% of cases, against 25% for the conventional protocol, with similar specificity (99.3–99.5% against 99.5%); the authors describe this as comparable or greater sensitivity, and the size of the gain differed between protocols. A 2011 study of one two-step immunoassay protocol reported 61% against 48% in early disease and 100% for all strategies in late disease. Interpretation is simpler — you get two clean positive/negative results instead of a long list of blot bands to count. And the second step is cheaper and faster to run, which lowers the turnaround time and the bill.

Because the gain is in early disease, the MTTT is usually described as the better fit for early or ambiguous presentations. Specificity (avoiding false positives) is roughly equivalent to STTT. Both are U.S. Centers for Disease Control and Prevention-endorsed as of 2019, and both are accepted for surveillance case definitions.

The Early-Window Problem

This is the single most important point in Lyme diagnostics, and patients who do not hear it explained clearly often suffer for it: serology is not reliable during the first few weeks of infection. Seroconversion — the moment your immune system starts making detectable antibodies against Borrelia — takes roughly two to six weeks after exposure. Before that window closes, you can have a textbook erythema migrans (EM) rash and still test stone-cold negative.

The published numbers are brutal. In early-localized disease (the EM stage), two-tier testing misses somewhere between 50% and 70% of cases, and one measured series did worse: conventional testing detected only 25% of 55 patients with acute EM rash (95% confidence interval 16–38%). In early-disseminated disease (weeks later, with multiple rashes or facial palsy), sensitivity climbs to 70–90%. Only in late disease — arthritis, chronic neurologic involvement — does sensitivity reach the 95–99% range.

The practical rule follows directly: the 2020 guideline from the Infectious Diseases Society of America, the American Academy of Neurology and the American College of Rheumatology recommends clinical diagnosis rather than laboratory testing for people with possible tick exposure in an endemic area who have a skin lesion compatible with an EM rash, and treatment follows that diagnosis without waiting for blood work. The rash is itself diagnostic under U.S. Centers for Disease Control and Prevention criteria. Ordering serology in this situation is actually counterproductive, because a negative result can wrongly be used to deny treatment or to second-guess a correct diagnosis. Testing has more to offer in later manifestations, ambiguous rashes, and disseminated presentations where antibodies have had time to develop.

Western Blot Band Interpretation

When STTT is used, the Western blot turns your result into a pattern of bands, each corresponding to a Borrelia protein of a particular molecular weight (measured in kilodaltons, kDa). The U.S. Centers for Disease Control and Prevention has standardized which bands "count."

Immunoglobulin M criteria (positive if any 2 of 3 bands are present): 23 kDa (OspC), 39 kDa (BmpA), and 41 kDa (flagellin). The 41 band is the least specific — many unrelated bacterial infections produce anti-flagellin antibodies — so a "41-only" result is not a positive blot.

Immunoglobulin G criteria (positive if any 5 of 10 bands are present): 18, 23 (OspC), 28, 30, 39 (BmpA), 41 (flagellin), 45, 58, 66, and 93 kDa.

A crucial caveat that patients almost always miss: the immunoglobulin M blot is only interpretable in the first 30 days of illness. After a month, immunoglobulin M antibodies that persist can reflect old, resolved infection, cross-reactivity, or nonspecific B-cell activity. Using a positive immunoglobulin M blot to diagnose Lyme at four months of symptoms is a common lab error that leads to misdiagnosis. After 30 days, you need immunoglobulin G positivity to call it Lyme.

False Positives — Other Causes

Antibody tests see shapes, not identity, and many proteins from unrelated organisms resemble Borrelia closely enough to trigger a positive ELISA or a few Western blot bands. Known sources of cross-reactivity include:

This is why a single band — especially the 41 band — is never enough to call a blot positive, and why isolated immunoglobulin M findings late in an illness rarely mean what they appear to mean.

When Testing Helps — And When It Does Not

Where the guideline does not use testing: patients with a classic EM rash in an endemic region. The rash is the diagnosis. A negative test is misleading; a positive test adds nothing.

Where testing is used:

Serology performs poorly as a screen in low-prevalence areas or in patients with only nonspecific fatigue and aches. The 2020 guideline says "clinicians should be selective when ordering tests in patients with a low probability of Lyme disease." The pretest probability is too low and false positives dominate the result.

Polymerase Chain Reaction Testing

Polymerase chain reaction (PCR) directly amplifies Borrelia DNA, bypassing the antibody problem entirely. If you find the DNA, the organism is there. The catch is that Borrelia rarely circulates in the blood in high numbers and rapidly moves into tissues, so blood polymerase chain reaction is almost useless — sensitivity is in the single digits.

Polymerase chain reaction is genuinely valuable on the right sample:

A negative polymerase chain reaction on any sample does not exclude Lyme. A positive result on an appropriately chosen sample is highly meaningful.

Culture

Culturing B. burgdorferi from a patient is technically possible on specialized Barbour-Stoenner-Kelly H (BSK-H) medium but is not clinically useful. Culture takes weeks, requires reference-lab conditions, has poor sensitivity except on skin-biopsy material, and is used almost exclusively for research. A "Lyme culture" ordered on blood falls outside that research use, so the result says little without knowing what the laboratory actually did.

Cerebrospinal Fluid Testing for Neuroborreliosis

When Lyme reaches the central nervous system — causing meningitis, radiculitis, cranial neuritis, or encephalopathy — a lumbar puncture is often necessary. See the neuroborreliosis article for the full clinical picture. Four cerebrospinal fluid findings build the diagnosis:

Polymerase chain reaction on cerebrospinal fluid adds specificity but not sensitivity. The antibody index is the workhorse of central nervous system (CNS) Lyme diagnosis, especially in Europe where clinical neuroborreliosis is more common.

A newer spinal fluid marker, the signalling protein CXCL13, has been studied for early diagnosis of Lyme infection of the nervous system. A pooled analysis of 7 studies with 1,299 people, 343 of them with the infection, concluded that it has high sensitivity and specificity; its abstract gives no pooled figures. In a 2014 Finnish series, median CXCL13 in spinal fluid fell from 16,770 pg/mL before treatment to 109 pg/mL after it. CXCL13 is not one of the four findings listed above.

C6 Peptide ELISA

The C6 peptide ELISA is a single-tier immunoassay that targets a short invariant region of the VlsE protein. It has been extensively validated and offers sensitivity roughly comparable to STTT in early-disseminated and late disease, with a simple one-step workflow. Specificity is slightly lower than two-tier testing, so a positive C6 is generally confirmed with a standard or modified two-tier algorithm before treatment decisions are made. It can be useful when lab turnaround matters and as one component of MTTT panels.

"Chronic Lyme" Tests Outside the CDC Criteria

This section is going to be blunt, and it is written for patients who are sick, scared, and being told by every mainstream doctor that their labs are "normal." You deserve honesty, not dismissal. But you also deserve to know what the tests you are spending thousands of dollars on actually measure.

Some specialty laboratories market Lyme panels that do not follow U.S. Centers for Disease Control and Prevention criteria. These reports often show bands or findings that sound damning — "positive immunoglobulin M," "reactive bands 31 and 34," "detected by nanotrap" — and the interpretation paragraph frequently suggests active Lyme infection.

The problems with these panels are real and documented:

None of this means your symptoms are imagined. Many patients with genuine post-treatment Lyme disease syndrome, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), mast cell activation, dysautonomia, or untreated co-infections end up at these labs because nobody else is listening. The problem is not your search for answers. The problem is that a positive result from a lab using non-standard criteria is not the same kind of evidence as a positive U.S. Centers for Disease Control and Prevention-validated test, and long courses of intravenous (IV) antibiotics based on those results carry real harm — Clostridioides difficile infection, line sepsis, fungal bloodstream infection, and gallbladder disease from ceftriaxone have all been reported in this setting. A 2017 federal report describes five patients with serious infections during treatment for chronic Lyme disease; one died of septic shock from a bloodstream infection linked to her central catheter, and the patient with Clostridioides difficile colitis later died of complications of amyotrophic lateral sclerosis, a diagnosis she already had. A 2000 case report describes a 30-year-old woman who died from a Candida parapsilosis septic clot on the tip of a catheter left in for 28 months for intravenous cefotaxime. A 1995 New Jersey hospital study found 25 patients with biliary disease, linked to ceftriaxone and higher daily doses; 14 had their gallbladders removed.

A report from one of these panels can be compared with the U.S. Centers for Disease Control and Prevention band lists above: bands counted outside those lists, and immunoglobulin M results read after 30 days of illness, are the points where it differs from the standard criteria. You deserve a careful second look, not a shrug.

Seronegative Lyme

Truly seronegative active Lyme disease — infection without detectable antibodies weeks into illness — is rare but real. It occurs most often in patients whose immune systems cannot mount a normal antibody response: those on B-cell-depleting drugs such as rituximab, patients with common variable immunodeficiency, and some post-transplant and human immunodeficiency virus-infected patients.

Diagnosis in this setting leans on direct-detection methods: skin-biopsy polymerase chain reaction, synovial-fluid polymerase chain reaction, cerebrospinal fluid findings, or characteristic imaging plus clinical picture. Empiric treatment is sometimes justified when the clinical story is strong enough despite negative serology. Outside this narrow immunocompromised context, a truly negative two-tier test weeks into an illness is strong evidence against active Lyme in an immunocompetent adult.

Post-Treatment Serology

This one catches patients repeatedly, and it causes enormous anxiety: antibodies against Borrelia persist for years — often for life — after successful treatment. A positive ELISA or blot six months, two years, or ten years after a cured infection does not mean the bacteria are still there. It simply means your immune system remembers.

The clinical corollary: re-testing serology cannot "see if the Lyme is gone." The result cannot answer that question. It will stay positive, and you will be scared for no reason. If you have persistent symptoms after treatment, the evaluation is clinical and focuses on identifying post-treatment Lyme disease syndrome, missed co-infections, or alternative diagnoses — not on re-running antibody panels.

The one exception is cerebrospinal fluid antibody index in suspected neuroborreliosis, which can decline after successful treatment and is occasionally used in Europe to monitor response. Even there, it is not a routine test, and a 2014 paper notes that the index can remain elevated for months after antibiotic treatment.

Special Populations

Pediatric patients. Children respond to serology similarly to adults, but EM rashes may be more subtle and easier to miss on dark skin or in the scalp. A strong clinical presentation in an endemic region is treated empirically; laboratory diagnosis follows the same two-tier or modified two-tier algorithm.

Pregnancy. Serology is interpreted identically in pregnancy. Early treatment of suspected Lyme in pregnant women is particularly important because untreated maternal Lyme has been associated with adverse pregnancy outcomes. Amoxicillin and cefuroxime are the preferred antibiotics; doxycycline is generally avoided in pregnancy. See the antibiotic protocols article for details.

Immunocompromised patients. Reduced antibody production means higher rates of false-negative serology. Rituximab recipients are the classic example; patients with common variable immunodeficiency, active chemotherapy, or advanced human immunodeficiency virus (HIV) are also at risk. Clinicians in this setting tend to have a lower threshold for direct-detection methods (polymerase chain reaction on appropriate samples) and empiric treatment when the picture fits.

Elderly patients. Serology performs well, but coexisting conditions (age-related antinuclear antibody positivity, chronic infections) increase the rate of nonspecific bands on Western blots. Interpretation leans on clinical features, not isolated serologic findings.

Key Research Papers

  1. Mead P, Petersen J, Hinckley A. Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep. 2019;68(32):703. — doi:10.15585/mmwr.mm6832a4
  2. Branda JA, Linskey K, Kim YA, Steere AC, Ferraro MJ. Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin Infect Dis. 2011;53(6):541-547. — doi:10.1093/cid/cir464
  3. Branda JA, et al. Advances in Serodiagnostic Testing for Lyme Disease Are at Hand. Clin Infect Dis. 2018;66(7):1133-1139. — doi:10.1093/cid/cix943
  4. Lantos PM, et al. Clinical Practice Guidelines by the IDSA, AAN, and ACR: 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Clin Infect Dis. 2021;72(1):e1-e48. — doi:10.1093/cid/ciaa1215
  5. Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med. 1994;330(4):229-234. — doi:10.1056/nejm199401273300401
  6. Branda JA, Strle K, Nigrovic LE, Lantos PM, Lepore TJ, Damle NS, Ferraro MJ, Steere AC. Evaluation of Modified 2-Tiered Serodiagnostic Testing Algorithms for Early Lyme Disease. Clin Infect Dis. 2017;64(8):1074-1080. — PubMed PMID: 28329259
  7. Yang J, Han X, Liu A, Bao F, Peng Y, Tao L, Ma M, Bai R, Dai X. Chemokine CXC Ligand 13 in Cerebrospinal Fluid Can Be Used as an Early Diagnostic Biomarker for Lyme Neuroborreliosis: A Meta-Analysis. J Interferon Cytokine Res. 2017;37(10):433-439. — PubMed PMID: 28972436
  8. Hytönen J, Kortela E, Waris M, Puustinen J, Salo J, Oksi J. CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation. J Neuroinflammation. 2014;11:103. — PubMed PMID: 24920219
  9. Marzec NS, Nelson C, Waldron PR, Blackburn BG, Hosain S, Greenhow T, Green GM, Lomen-Hoerth C, Golden M, Mead PS. Serious Bacterial Infections Acquired During Treatment of Patients Given a Diagnosis of Chronic Lyme Disease - United States. MMWR Morb Mortal Wkly Rep. 2017;66(23):607-609. — PubMed PMID: 28617768
  10. Patel R, Grogg KL, Edwards WD, Wright AJ, Schwenk NM. Death from inappropriate therapy for Lyme disease. Clin Infect Dis. 2000;31(4):1107-1109. — PubMed PMID: 11049799
  11. Ettestad PJ, Campbell GL, Welbel SF, Genese CA, Spitalny KC, Marchetti CM, Dennis DT. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis. 1995;171(2):356-361. — PubMed PMID: 7844372
  12. Strle F, Wormser GP. Early Lyme Disease (Erythema Migrans) and Its Mimics (Southern Tick-Associated Rash Illness and Tick-Associated Rash Illness). Infect Dis Clin North Am. 2022;36(3):523-539. — PubMed PMID: 36116832
  13. U.S. Centers for Disease Control and Prevention. Notice to Readers: Caution Regarding Testing for Lyme Disease. MMWR Morb Mortal Wkly Rep. 2005. — CDC: mm5405a6

PubMed Topic Searches

For further reading, the following PubMed topic searches return current peer-reviewed work on Lyme disease diagnostics, serology interpretation, and direct-detection methods:

  1. PubMed: Lyme disease two-tier testing
  2. PubMed: Modified two-tier testing for Lyme disease
  3. PubMed: Western blot Lyme disease criteria
  4. PubMed: CSF Lyme neuroborreliosis and antibody index
  5. PubMed: Borrelia burgdorferi PCR in synovial fluid
  6. PubMed: Seronegative Lyme disease and immunocompromised hosts
  7. PubMed: C6 peptide ELISA for Lyme disease
  8. PubMed: Lyme disease serology false positives and cross-reactivity

Back to Table of Contents

Connections

Back to Table of Contents